Overview

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Status:
RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Phase:
PHASE2
Details
Lead Sponsor:
Biohaven Therapeutics Ltd.